Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma
Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.
Patient Profile 3: A 68-Year-Old With Multiple Myeloma
The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.
Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease
Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.
Patient Profile 1: A 70-Year-Old With Multiple Myeloma
The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.
RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM
An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.
Talquetamab for Patients With Relapsed/Refractory MM
Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.
Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM
Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.
MM: Influence of CAR T-Cell Therapy on Clinical Care
The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.
CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.
Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times
A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.
Assessing Frailty in Multiple Myeloma
Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.
Treatment Strategies for Patients With Transplant-Ineligible MM
Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.
Transplant and Treatment Decision-Making in Multiple Myeloma
The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.
Multiple Myeloma: Data on Outcomes Based On Cytogenetics
Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.
Treatment Options for Patients With Newly Diagnosed Multiple Myeloma
A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.
The Role of Transplant in Newly Diagnosed Multiple Myeloma
A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.
